In cancer cells, the expression and interaction of EGFR and HER2 belong to the phenotypic heterogeneity of cancer cells [5,6,7,8], which leads, in combination with genetic heterogeneity, to drug resistance and disease progression [9,10,11]. This evidence concerns the gene ERBB2 and cancer.